BACKGROUND: Accurate and reproducible measurement of expression of pro-inflammatory cytokines in colonic biopsies from patients with ulcerative colitis (UC) is essential for proof-of-concept and mechanism-of-action studies. Few studies have rigorously established the number of biopsies required for accurate and reproducible biomarker measurements. AIM: To validate methods for measuring changes in gene expression in colonic biopsy samples. METHODS: Twelve colonic biopsies were obtained from each of six healthy controls, six patients with inactive UC and seven patients with active UC. Mayo endoscopic scores were used as a clinical reference standard. Quantitative PCR was used to assess mRNA expression of eight known inflammatory genes. The power to detect a reduction in gene expression in active vs. inactive UC was calculated using a linear mixed effect model. RESULTS: mRNA analysis of colonic biopsies is a sensitive and feasible approach for measuring inflammatory gene expression in colonic biopsies. Inflammatory biomarkers correlate with Mayo endoscopic subscores for each colonic region. For most genes, three rectal biopsies from two to four patients are required to detect changes in gene expression corresponding to active vs. inactive UC to achieve a power of 80% with an alpha of 0.05. CONCLUSION: Our data suggest that systematic measurement of inflammatory biomarkers at the mRNA level can be a valuable tool for hypothesis testing, and assessment of clinical activity and response to therapy in ulcerative colitis.
BACKGROUND: Accurate and reproducible measurement of expression of pro-inflammatory cytokines in colonic biopsies from patients with ulcerative colitis (UC) is essential for proof-of-concept and mechanism-of-action studies. Few studies have rigorously established the number of biopsies required for accurate and reproducible biomarker measurements. AIM: To validate methods for measuring changes in gene expression in colonic biopsy samples. METHODS: Twelve colonic biopsies were obtained from each of six healthy controls, six patients with inactive UC and seven patients with active UC. Mayo endoscopic scores were used as a clinical reference standard. Quantitative PCR was used to assess mRNA expression of eight known inflammatory genes. The power to detect a reduction in gene expression in active vs. inactive UC was calculated using a linear mixed effect model. RESULTS: mRNA analysis of colonic biopsies is a sensitive and feasible approach for measuring inflammatory gene expression in colonic biopsies. Inflammatory biomarkers correlate with Mayo endoscopic subscores for each colonic region. For most genes, three rectal biopsies from two to four patients are required to detect changes in gene expression corresponding to active vs. inactive UC to achieve a power of 80% with an alpha of 0.05. CONCLUSION: Our data suggest that systematic measurement of inflammatory biomarkers at the mRNA level can be a valuable tool for hypothesis testing, and assessment of clinical activity and response to therapy in ulcerative colitis.
Authors: Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn Journal: Gastroenterology Date: 2011-06-30 Impact factor: 22.682
Authors: Ingrid Arijs; Gert De Hertogh; Kathleen Machiels; Kristel Van Steen; Katleen Lemaire; Anica Schraenen; Leentje Van Lommel; Roel Quintens; Gert Van Assche; Séverine Vermeire; Frans Schuit; Paul Rutgeerts Journal: Am J Gastroenterol Date: 2011-02-15 Impact factor: 10.864
Authors: Brian G Feagan; William J Sandborn; Geert D'Haens; Suresh Pola; John W D McDonald; Paul Rutgeerts; Pia Munkholm; Ulrich Mittmann; Debra King; Cindy J Wong; Guangyong Zou; Allan Donner; Lisa M Shackelton; Denise Gilgen; Sigrid Nelson; Margaret K Vandervoort; Marianne Fahmy; Edward V Loftus; Remo Panaccione; Simon P Travis; Gert A Van Assche; Séverine Vermeire; Barrett G Levesque Journal: Gastroenterology Date: 2013-03-22 Impact factor: 22.682
Authors: Alberto J León; Emma Gómez; Jose A Garrote; David Bernardo; Asterio Barrera; Jose L Marcos; Luis Fernández-Salazar; Benito Velayos; Alfredo Blanco-Quirós; Eduardo Arranz Journal: Mediators Inflamm Date: 2009-07-30 Impact factor: 4.711
Authors: M H Buch; D L Boyle; S Rosengren; B Saleem; R J Reece; L A Rhodes; A Radjenovic; A English; H Tang; G Vratsanos; P O'Connor; G S Firestein; P Emery Journal: Ann Rheum Dis Date: 2008-09-04 Impact factor: 19.103
Authors: Brigid S Boland; David L Boyle; William J Sandborn; Gary S Firestein; Barrett G Levesque; Joshua Hillman; Bing Zhang; James Proudfoot; Lars Eckmann; Peter B Ernst; Jesus Rivera-Nieves; Suresh Pola; Nedret Copur-Dahi; Guangyong Zou; John T Chang Journal: Inflamm Bowel Dis Date: 2015-02 Impact factor: 5.325
Authors: Martin Geoffrey Thomas; Carrie Bayliss; Simon Bond; Francis Dowling; James Galea; Vipul Jairath; Christopher Lamb; Christopher Probert; Elizabeth Timperley-Preece; Alastair Watson; Lynne Whitehead; John G Williams; Miles Parkes; Arthur Kaser; Tim Raine Journal: BMJ Open Date: 2019-02-15 Impact factor: 2.692
Authors: Wael N Sayej; Antoine Ménoret; Anu S Maharjan; Marina Fernandez; Zhu Wang; Fabiola Balarezo; Jeffrey S Hyams; Francisco A Sylvester; Anthony T Vella Journal: Clin Transl Immunology Date: 2016-07-01